Takeda has reported positive results from its phase 3 G-HOPE-001 trial of anti-CLDN18.2 drug arcotatug tavatecan (TAK-921) in ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive ...

In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...

An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...

China has firmly emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could ...

Roche's drugs business brought in CHF 11.47 billion (nearly $14 billion) in the three months, slightly ahead of analyst ...

Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

Despite a string of US policy initiatives designed to curb medicine pricing under recent administrations, the annual cost of ...

The AD-SMART trial – which has started to recruit people aged over 55 with a diagnosis of Alzheimer's or mixed dementia – ...